^
    Back
    Association details:
    Biomarker:GLI1 overexpression
    Cancer:Basal Cell Carcinoma
    Drug:Erivedge (vismodegib) (Hedgehog cell-signalling pathway inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancer Cell
    Title:

    Smoothened variants explain the majority of drug resistance in basal cell carcinoma

    Excerpt:
    ...resistant BCCs had high GLI1 mRNA levels despite concurrent treatment with vismodegib (p=0.0001). Immunofluorescence for GLI1 revealed elevated levels of GLI1 protein in resistant BCCs compared to sensitive tumors, confirming persistent HH signaling in resistant BCCs at the protein level…
    DOI:
    10.1016/j.ccell.2015.02.002